Difference between revisions of "Ponatinib (Iclusig)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "[http://online.lexi.com/ Lexicomp]" to "Lexicomp") |
||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
==Toxicity management== | ==Toxicity management== | ||
*2013-10-31: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm373072.htm Suspended by FDA] because of the risk of life-threatening blood clots and severe narrowing of blood vessels. | *2013-10-31: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm373072.htm Suspended by FDA] because of the risk of life-threatening blood clots and severe narrowing of blood vessels. | ||
| − | *2013-12-20: [http://www.iclusigrems.com/ REMS] program put in place and medication is once again available. | + | *2013-12-20: [http://www.iclusigrems.com/ REMS] program put in place and medication is once again available; REMS was discontinued in August 2018. |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 15: | Line 15: | ||
==Patient drug information== | ==Patient drug information== | ||
*[https://www.iclusig.com/pdf/ICLUSIG-Prescribing-Information.pdf Ponatinib (Iclusig) package insert]<ref name="insert"></ref> | *[https://www.iclusig.com/pdf/ICLUSIG-Prescribing-Information.pdf Ponatinib (Iclusig) package insert]<ref name="insert"></ref> | ||
| − | *[https://chemocare.com/ | + | *[https://chemocare.com/druginfo/ponatinib.aspx Ponatinib (Iclusig) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/ponatinib.aspx Ponatinib (Iclusig) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/ponatinib-patient-drug-information Ponatinib (Iclusig) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ponatinib-patient-drug-information Ponatinib (Iclusig) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/ponatinib-patient-drug-information Ponatinib (Iclusig) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ponatinib-patient-drug-information Ponatinib (Iclusig) patient drug information (UpToDate)]</ref> | ||
| Line 21: | Line 21: | ||
*2012-12-14: Accelerated approval for the treatment of adult patients with chronic phase, accelerated phase, or blast phase [[Chronic myeloid leukemia|chronic myeloid leukemia (CML)]] that is resistant or intolerant to prior [[Regimen_classes#Tyrosine_kinase_inhibitor_therapy|tyrosine kinase inhibitor therapy]] ''(Based on OPTIC)'' | *2012-12-14: Accelerated approval for the treatment of adult patients with chronic phase, accelerated phase, or blast phase [[Chronic myeloid leukemia|chronic myeloid leukemia (CML)]] that is resistant or intolerant to prior [[Regimen_classes#Tyrosine_kinase_inhibitor_therapy|tyrosine kinase inhibitor therapy]] ''(Based on OPTIC)'' | ||
*2012-12-14: Accelerated approval for the treatment of adult patients with [[Biomarkers#BCR-ABL1|Philadelphia chromosome positive]] [[:Category:Acute lymphoblastic leukemias|acute lymphoblastic leukemia]] (Ph+ ALL) that is resistant or intolerant to prior [[Regimen_classes#Tyrosine_kinase_inhibitor_therapy|tyrosine kinase inhibitor therapy]]. ''(Based on PACE)'' | *2012-12-14: Accelerated approval for the treatment of adult patients with [[Biomarkers#BCR-ABL1|Philadelphia chromosome positive]] [[:Category:Acute lymphoblastic leukemias|acute lymphoblastic leukemia]] (Ph+ ALL) that is resistant or intolerant to prior [[Regimen_classes#Tyrosine_kinase_inhibitor_therapy|tyrosine kinase inhibitor therapy]]. ''(Based on PACE)'' | ||
| − | *2016-11-29: Granted full approval for the treatment of adult patients with chronic-phase, accelerated-phase, or blast-phase [[Chronic myeloid leukemia | chronic myeloid leukemia (CML)]] or [[Biomarkers#BCR-ABL1|Philadelphia | + | *2016-11-29: Granted full approval for the treatment of adult patients with chronic-phase, accelerated-phase, or blast-phase [[Chronic myeloid leukemia | chronic myeloid leukemia (CML)]] or [[Biomarkers#BCR-ABL1|Philadelphia chromosome-positive]] [[:Category:Acute lymphoblastic leukemias| acute lymphoblastic leukemia (ALL)]] for whom no other tyrosine kinase inhibitor therapy is indicated. ''(Based on PACE)'' |
| − | *2016-11-29: Granted full approval for the treatment of adult patients with [[Biomarkers#T315I|T315I]] | + | *2016-11-29: Granted full approval for the treatment of adult patients with [[Biomarkers#T315I|T315I]]-positive [[Chronic myeloid leukemia|CML]] (chronic phase, accelerated phase, or blast phase). ''(Based on PACE)'' |
| − | *2016-11-29: Granted full approval for the treatment of adult patients with [[Biomarkers#T315I|T315I]]-positive, [[Biomarkers#BCR-ABL1|Philadelphia | + | *2016-11-29: Granted full approval for the treatment of adult patients with [[Biomarkers#T315I|T315I]]-positive, [[Biomarkers#BCR-ABL1|Philadelphia chromosome-positive]] [[:Category:Acute lymphoblastic leukemias|ALL]]. ''(Based on PACE)'' |
| + | *2024-03-19: Granted accelerated approval in combination with chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive [[:Category:Acute lymphoblastic leukemias|acute lymphoblastic leukemia]] (Ph+ ALL). ''(Based on PhALLCON)'' | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
*2013-07-01: Initial authorization | *2013-07-01: Initial authorization | ||
| Line 29: | Line 30: | ||
*2015-04-02: Initial notice of compliance with conditions | *2015-04-02: Initial notice of compliance with conditions | ||
*2022-10-03: Conditions were met | *2022-10-03: Conditions were met | ||
| + | ==History of changes in PMDA indication== | ||
| + | *2016-09-28: New approval for the treatment of [[Chronic myeloid leukemia|chronic myelogenous leukemia]] with resistance or intolerance to prior drug therapies. | ||
| + | *2016-09-28: New approval for the treatment of recurrent or refractory Philadelphia chromosome-positive [[:Category:Acute lymphoblastic leukemias|acute lymphoblastic leukemia]]. | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' | + | *'''Code name:''' AP-24534 |
*'''Generic name:''' ponatinib hydrochloride | *'''Generic name:''' ponatinib hydrochloride | ||
*'''Brand name:''' Iclusig | *'''Brand name:''' Iclusig | ||
| Line 54: | Line 58: | ||
[[Category:Chronic myeloid leukemia medications]] | [[Category:Chronic myeloid leukemia medications]] | ||
| − | |||
[[Category:FDA approved in 2012]] | [[Category:FDA approved in 2012]] | ||
[[Category:EMA approved in 2013]] | [[Category:EMA approved in 2013]] | ||
[[Category:Health Canada approved in 2015]] | [[Category:Health Canada approved in 2015]] | ||
| − | [[Category:PMDA approved | + | [[Category:PMDA approved in 2016]] |
Latest revision as of 12:05, 29 June 2024
General information
Class/mechanism: Tyrosine kinase inhibitor with multiple targets, including Bcr-Abl tyrosine kinase, the constitutively active tyrosine kinase resulting from the Philadelphia chromosome abnormality in CML, as well as VEGFR, PDGFR, FGFR, the SRC kinases, KIT, EPH receptors, RET, TIE2, and FLT3. Ponatinib is active against the Bcr-Abl T315I mutation.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Toxicity management
- 2013-10-31: Suspended by FDA because of the risk of life-threatening blood clots and severe narrowing of blood vessels.
- 2013-12-20: REMS program put in place and medication is once again available; REMS was discontinued in August 2018.
Diseases for which it is used
Patient drug information
- Ponatinib (Iclusig) package insert[1]
- Ponatinib (Iclusig) patient drug information (Chemocare)[4]
- Ponatinib (Iclusig) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 2012-12-14: Accelerated approval for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy (Based on OPTIC)
- 2012-12-14: Accelerated approval for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy. (Based on PACE)
- 2016-11-29: Granted full approval for the treatment of adult patients with chronic-phase, accelerated-phase, or blast-phase chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) for whom no other tyrosine kinase inhibitor therapy is indicated. (Based on PACE)
- 2016-11-29: Granted full approval for the treatment of adult patients with T315I-positive CML (chronic phase, accelerated phase, or blast phase). (Based on PACE)
- 2016-11-29: Granted full approval for the treatment of adult patients with T315I-positive, Philadelphia chromosome-positive ALL. (Based on PACE)
- 2024-03-19: Granted accelerated approval in combination with chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). (Based on PhALLCON)
History of changes in EMA indication
- 2013-07-01: Initial authorization
History of changes in Health Canada indication
- 2015-04-02: Initial notice of compliance with conditions
- 2022-10-03: Conditions were met
History of changes in PMDA indication
- 2016-09-28: New approval for the treatment of chronic myelogenous leukemia with resistance or intolerance to prior drug therapies.
- 2016-09-28: New approval for the treatment of recurrent or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
Also known as
- Code name: AP-24534
- Generic name: ponatinib hydrochloride
- Brand name: Iclusig
References
Categories:
- Drugs
- Oral medications
- Mutation-specific medications
- Bcr-Abl inhibitors
- FGFR inhibitors
- FLT3 inhibitors
- KIT inhibitors
- RET inhibitors
- SRC inhibitors
- VEGFR inhibitors
- PDGFR inhibitors
- B-cell acute lymphoblastic leukemia medications
- Chronic myeloid leukemia medications
- FDA approved in 2012
- EMA approved in 2013
- Health Canada approved in 2015
- PMDA approved in 2016